FDA approves Bayer's Adempas for two forms of pulmonary hypertension

theflyonthewall.com

The FDA approved Adempas to treat adults with two forms of pulmonary hypertension. The FDA reviewed Adempas under its priority review program, which provides for an expedited six-month review of drugs that may offer major advances in treatment. Adempas is marketed by Bayer HealthCare Pharmaceuticals.

View Comments